Medivation’s hostile fight with bidder Sanofi is over, and a new sale process has just begun.

Troubled Valeant may have a buyer to help it pull off some of the asset sales it’s been touting as it looks to cut down its debt pile.

Plenty of Big Pharma players are reportedly eying Medivation. But who’s most likely to make a bid?

Tesaro’s good fortune may be Big Pharma’s bad luck. The biotech posted “overwhelmingly positive” data on its PARP inhibitor niraparib, boosting hopes for…

Some specialty pharma companies have recently put the brakes on dealmaking--but Horizon Pharma, on the other hand, may be gearing up for more.

Teva’s massive deal to buy Allergan’s generics business continues to ripple its way through the industry. Australia’s Mayne Pharma has scooped up 42 products…

Acquisitions are complicated, but swaps must be more so; they’re essentially buyouts times two. Case in point: Sanofi and Boehringer Ingelheim, which announced…

Medivation isn’t the only one that’s not into Sanofi’s attempts to overhaul the biotech’s board. Proxy adviser Glass Lewis isn’t feeling it, either.

Depomed’s okay with a special meeting, at which a rebel shareholder hopes to wipe its board clean. It just doesn’t want to do it for another four months.